Loading...

Calliditas Therapeutics AB (publ)

CALT•NASDAQ
Healthcare
Biotechnology
$40.000
$-0.04(-0.10%)
U.S. Market opens in NaNh NaNm

Calliditas Therapeutics AB (publ) (CALT) Stock Overview

Explore Calliditas Therapeutics AB (publ)’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

Z

Key Financials

Market Cap2.1B
P/E Ratio-21.16
EPS (TTM)$-1.76
ROE-0.85%
Fundamental Analysis

AI Price Forecasts

1 MonthN/A
3 MonthsN/A
1 Year Target$50.22

CALT Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of Calliditas Therapeutics AB (publ) (CALT) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

Our forecasting models predict significant price movements, with a 12-month target of $50.22.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -21.16 and a market capitalization of 2.1B. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

1-Day Change
N/A
5-Day Change
N/A
1-Month Change
N/A
3-Month Change
3.12%
6-Month Change
113.90%
Year-to-Date (YTD) Change
60.000%
1-Year Change
129.16%
3-Year Change
75.06%
5-Year Change
104.08%
All-Time (Max) Change
104.08%

Contact Information

https://www.calliditas.se
46 84 11 30 05
Kungsbron 1, D5, Stockholm, NaN, 111 22

Company Facts

2,220 Employees
IPO DateJun 5, 2020
CountrySE

Frequently Asked Questions